Vista Pharmaceuticals Ltd (524711)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Vista Pharmaceuticals' revenue was ₹0.0 Cr (-100.0% year on year, -100.0% on the previous quarter), and net profit ₹-5.9 Cr (a bigger loss than a year earlier).
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | -100.0% | -100.0% |
| Operating profit | ₹-7.1 | loss widened | loss widened |
| Net profit | ₹-5.9 | loss widened | loss widened |
| EPS (₹) | -0.95 | loss widened | loss widened |
📢 Recent Corporate Announcements
Vista Pharmaceuticals reported zero revenue from operations for the quarter ended June 30, 2026, compared to Rs 1.52 crore in the same period last year. The company posted a net loss of Rs 98.59 lakhs, marking its sixth consecutive year of losses. Lenders have classified the company's credit facilities as Non-Performing Assets (NPAs) due to defaults exceeding 90 days, resulting in frozen working capital accounts. Management is banking on a pending Rs 9.22 crore warrant conversion due by September 15, 2026, to sustain operations and negotiate debt restructuring.
- Revenue from operations dropped to Nil from Rs 1.52 crore in the previous year's corresponding quarter.
- Credit facilities classified as NPA by lenders, leading to a freeze on all working capital accounts.
- Current liabilities exceed current assets by Rs 1.83 crore, with a net loss reported for the sixth consecutive year.
- Outstanding statutory dues include Rs 33.15 lakhs in unpaid Provident Fund and Rs 7.16 lakhs in TDS.
- Management expects Rs 9.22 crore in warrant call money by September 15, 2026, to meet operational obligations.
Vista Pharmaceuticals reported zero revenue from operations for the quarter ended June 30, 2026, a sharp decline from Rs 1.52 Cr in the previous year's corresponding quarter. The company posted a net loss of Rs 0.99 Cr, marking its sixth consecutive year of losses. Critically, its credit facilities have been classified as Non-Performing Assets (NPAs) by lenders due to debt servicing defaults exceeding 90 days, resulting in frozen working capital accounts. The company's survival depends on receiving Rs 9.22 Cr in warrant call money due by September 15, 2026.
- Revenue from operations dropped to Nil for the quarter compared to Rs 1.52 Cr in June 2025.
- Net loss for the quarter stood at Rs 0.99 Cr, contributing to a negative working capital of Rs 1.83 Cr.
- Credit facilities classified as NPA by lenders, leading to a freeze on all working capital accounts.
- Outstanding statutory liabilities include Rs 33.15 lakh in Provident Fund and Rs 7.16 lakh in TDS.
- Management is awaiting Rs 9.22 Cr in warrant subscription money due before September 15, 2026, to sustain operations.
Vista Pharmaceuticals has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position, having reported zero revenue in the preceding quarter (March 2026) and a total TTM loss of Rs 12 crore. With a small market capitalization of Rs 41 crore and an operating profit margin of -270.4%, these results are critical for assessing the company's operational viability.
- Board meeting scheduled for August 14, 2026, to approve Q1 results.
- Company reported Rs 0.0 revenue in the most recent quarter (March 2026).
- TTM Net Profit is a loss of Rs 12 crore against a revenue of only Rs 5 crore.
- Promoter holding remains low at 21.19% as of March 2026.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
